Image may be NSFW.
Clik here to view.
Clik here to view.
Stifel starts Tracon Pharma at buy
Stifel has launched coverage of Tracon Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $16 target price, saying the company predominantly develops cancer drugs that make other cancer drugs work...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Stifel ups Tracon Pharma price target to $20
Stifel has raised its price target for Tracon Pharmaceuticals (NASDAQ:TCON) to $20 from $16 after the company updated results from its Phase 1b trial in advanced renal cell carcinoma (RCC). The stock...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Roth starts Tracon Pharma at buy
Roth Capital Partners has initiated coverage of Tracon Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $18 price target, calling the company an intriguing play in the $16-billion anti-VEGF...
View Article
More Pages to Explore .....
